Advisors of the American Medical Association (AMA) Current Procedural Terminology (CPT) and Relative Value Update (RUC) Committees play a crucial role in the code creation and valuation process. These positions allow the ACR to have a significant voice in influencing changes and ensuring rheumatology services are effectively represented.
Payer audits and coding scrutiny are in full swing after an influx of fraudulent claims during the COVID-19 pandemic. Make sure your coding practices are in compliance to protect your revenue.
In 2022, rheumatology practices should prepare for documentation, coding, billing and reimbursement revisions related to evaluation and management (E/M), split/shared billing policies and telehealth services.
Enabling rheumatology practices to use complex administration codes for biologic drugs is critical for maintaining patient access to essential therapies.
Healthcare law is ever changing, particularly with regard to price transparency. Key healthcare leaders and stakeholders have long argued for more stringent price transparency regulations in an effort to increase patient awareness regarding the cost of a hospital item or service prior to receiving the service. Such information is anticipated to enable patients to take…
Participation in the American Medical Association Relative Value Update Committee surveys contributes to the accurate valuation of rheumatology services.
Selected ACR members will be invited to participate in a survey from the AMA Relative Value Update Committee. If you do, respond by the listed date. Data from these surveys helps set Medicare and other payer reimbursement rates.
New and updated FY22 diagnosis codes became effective for encounters on or after Oct. 1, 2021, including key updates for Sjögren syndrome and non-radiographic axial spondyloarthritis.
Coding questions and billing compliance are just a few of the issues ACR practice management specialists can help managers and rheumatologists navigate to recoup reimbursement and ensure timely patient treatment.
The ACR sent a letter to CVS Caremark detailing how recent updates to its prior authorization forms for many biologic drugs are increasing the paperwork burden for rheumatology practices and hurting patients’ timely access to treatment.